The literature article entitled, "cemented proximal femoral replacement for the management of non-neoplastic conditions: a versatile implant but not without its risks" written by christopher fenelon, mb bch, mch, mrcsi, evelyn p.
Murphy, mb bch, mch, mrcsi, stephen r.
Kearns, mb bch, md, frcsi, william curtin, mb bch, frcsi, and colin g.
Murphy, mb bch, bao, frcsi published by the journal of arthroplasty published online 10 september 2019 was reviewed.
The article's purpose was to assess the reoperation, complication, and mortality rates following cemented proximal femoral replacement (pfr) for treatment of nonneoplastic conditions.
Data was compiled from multi-surgeon observational study of patients treated with a pfr between january 1, 2018 and december 31, 2018 in galway university hospital (79 pfrs).
Indication for pfr was mostly commonly for periprosthetic fractures and revision total hip arthroplasty (tha) but also were performed for hemiarthroplasties.
Article reports 35 patients received acetabular revision but does not specify or identify products utilized indicating some original acetabular components were left intact or non-existent.
All other original implants are unknown and not identified.
Article reports pfr procedures utilized either depuy lps system (55) or a non-depuy system (24) for proximal femoral replacement.
The article does not clarify which specific products are associated with the generalized adverse events.
As the article does not identify any other components (acetabular or femoral head) or the existing acetabular components, only the proximal body and stem will be captured within this complaint for depuy lps.
Cement manufacturer is not identified.
Adverse events for those not identified are captured as generalized adverse events and accurate quantities cannot be determined due to inadequate information provided.
The article examines deaths in the first 30-day period (table 3 with identified products and patient identifiers) and provided asa (american society of anesthesiologists) and bcis (bone cement implantation syndrome) grades as predictors of mortality.
It is noted that all patients had an asa score of 3 or 4, and four of the patients had "extensive cardiopulmonary conditions" indicated by a bcis score of 3.
The article also provides information for those who experienced dislocation (table 2 with identified products and patient identifiers) but does not identify acetabular or femoral head components.
Figures 1-5 provide radiographic images of identified patients but no identification on brand name products utilized.
The caption description does not indicate any adverse events associated with the pfr procedures.
Depuy products: lps proximal body, lps femoral stem.
Deaths from table 3: patient no 1, (b)(6) female diagnosed with comminuted proximal femoral fracture, asa grade 4, bmi 22, bcis grade 3 with lps implant, olsen predictors (chf, atrial fibrillation, beta blocker, ace inhibitor, and warfarin) died within 24 hours of operative day.
Patient no 2, (b)(6) female diagnosed with periprosthetic fracture (original implants unknown) of vancouver b3 for uncemented tha 8 years in situ, asa grade 3, bmi 41, bcis grade 3 with lps implant, olsen predictors (chf, atrial fibrillation, bet blocker, ace inhibitor, diuretics) died within 24 hours of operative day.
Patient no 5, (b)(6) female diagnosed with periprosthetic fracture (original implants unknown) of vancouver b3 for uncemented tha 5 years in situ, asa grade 3, bmi 22, bcis grade 3 with lps implant, olsen predictors (none listed) died 19 days postop.
Generalized adverse events: venous thromboembolism (no indication of intervention), pulmonary embolus (no indication of intervention), deep venous thrombosis (no indication of intervention), prosthetic joint infection (successfully managed with long-term suppressive oral antibiotics, dislocations (treated by closed reductions, conservative management or revision of liner and femoral head).
|